Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DH001 for prevention of doxorubicin-related cardiotoxicity in cancer patients
CTR20232122Phase 2Active
- Sponsor
- Dinghui Pharmaceutical
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DH001 in Cardiotoxicity, sponsored by Dinghui Pharmaceutical. Started Sep 2023; status: active.
02
Drugs
DH001
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on CTR20232122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232122.